secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061525
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics reports Q3 2023 net loss of $23.0M; cash runway into 2026
----------------------------------------------------------------------------

- Net loss $23.0M in Q3 2023 vs $16.2M in Q3 2022; revenue $3.9M (up from $3.4M) from collaboration.
- Cash, equivalents, and marketable securities $215.4M as of Sept 30; funding operations into 2026.
- FDA cleared IND for TSC-203-A0201 targeting PRAME; plans to file two additional INDs by year-end.
- Expects initial heme program data at ASH Dec 2023; solid tumor Phase 1 enrollment by year-end 2023.
- R&D expenses $22.7M, up $7.7M YoY due to clinical start-up costs and personnel expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/0000950170-23-061525-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017023061525/tcrx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061525

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer